NYSE:AMRX Amneal Pharmaceuticals - AMRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Amneal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.33 +0.02 (+1.53%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.28▼$1.3450-Day Range$1.31▼$2.7052-Week Range$1.28▼$4.60Volume562,247 shsAverage Volume1.10 million shsMarket Capitalization$403.81 millionP/E RatioN/ADividend YieldN/APrice Target$3.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Amneal Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside175.7% Upside$3.67 Price TargetShort InterestHealthy7.15% of Float Sold ShortDividend StrengthN/ASustainability-2.51Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings Growth2.00%From $0.50 to $0.51 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector339th out of 989 stocksPharmaceutical Preparations Industry150th out of 480 stocks 3.3 Analyst's Opinion Consensus RatingAmneal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.67, Amneal Pharmaceuticals has a forecasted upside of 175.7% from its current price of $1.33.Amount of Analyst CoverageAmneal Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.15% of the float of Amneal Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmneal Pharmaceuticals has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Amneal Pharmaceuticals has recently decreased by 11.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmneal Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmneal Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmneal Pharmaceuticals has received a 47.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services", "Capecitabine", "Low-ceiling diuretics", "Memantine", "Arsenic trioxide", and "Hydroxychloroquine" products. See details.Environmental SustainabilityThe Environmental Impact score for Amneal Pharmaceuticals is -2.51. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Amneal Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for AMRX on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Amneal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amneal Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders26.78% of the stock of Amneal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 32.79% of the stock of Amneal Pharmaceuticals is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Amneal Pharmaceuticals are expected to grow by 2.00% in the coming year, from $0.50 to $0.51 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amneal Pharmaceuticals is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amneal Pharmaceuticals is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAmneal Pharmaceuticals has a PEG Ratio of 0.12. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAmneal Pharmaceuticals has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amneal Pharmaceuticals (NYSE:AMRX) StockAmneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.Read More Receive AMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRX Stock News HeadlinesMarch 20, 2023 | americanbankingnews.comAmneal Pharmaceuticals (NYSE:AMRX) Earns Hold Rating from Analysts at StockNews.comMarch 16, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Amneal Pharmaceuticals (NASDAQ:AMRX)March 25, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 6, 2023 | finance.yahoo.comAmneal Pharmaceuticals, Inc. (NYSE:AMRX) Q4 2022 Earnings Call TranscriptMarch 4, 2023 | seekingalpha.comAmneal Pharmaceuticals, Inc. (AMRX) Q4 2022 Earnings Call TranscriptMarch 4, 2023 | benzinga.comAmneal Pharmaceuticals Stock (NYSE:AMRX), Short Interest ReportMarch 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX) and Puma Biotechnology (PBYI)March 3, 2023 | finance.yahoo.comQ4 2022 Amneal Pharmaceuticals Inc Earnings CallMarch 25, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 2, 2023 | msn.comAmneal Pharmaceuticals Non-GAAP EPS of $0.23 beats by $0.02, revenue of $610M beats by $30.07MMarch 2, 2023 | finance.yahoo.comAmneal Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 2, 2023 | finance.yahoo.comAmneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mgJanuary 31, 2023 | finance.yahoo.comAmneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023January 29, 2023 | forbes.comAmneal PharmaceuticalsJanuary 25, 2023 | msn.comIntercept Pharma gains after patent settlement with AmnealJanuary 25, 2023 | finance.yahoo.comIntercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 YearsJanuary 23, 2023 | seekingalpha.comAmneal Pharmaceuticals: Risk Still PersistsJanuary 12, 2023 | finance.yahoo.comUS Releases Stockpiled Tamiflu Supplies Amid Cold, Flu Treatment ShortagesJanuary 4, 2023 | finance.yahoo.comAmneal Announces Strategic European Partnership with Orion CorporationDecember 20, 2022 | finance.yahoo.comShareholders in Amneal Pharmaceuticals (NYSE:AMRX) have lost 54%, as stock drops 13% this past weekDecember 20, 2022 | finance.yahoo.comAmneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag ApprovalDecember 7, 2022 | reuters.comValue Drug's subpoenas against Amneal's ex-lawyers are 'intrusive,' they argueNovember 23, 2022 | finance.yahoo.comAmneal to Participate at Upcoming Investor ConferencesNovember 22, 2022 | finance.yahoo.comAmneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United StatesNovember 14, 2022 | finance.yahoo.comFDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For ReviewNovember 11, 2022 | markets.businessinsider.comAmneal Pharma: FDA To Evaluate NDA For IPX203 In Treatment Of Parkinson's DiseaseNovember 9, 2022 | finance.yahoo.comAmneal Pharmaceuticals Third Quarter 2022 Earnings: Misses ExpectationsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRX Company Calendar Last Earnings3/02/2023Today3/24/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:AMRX CUSIPN/A CIK1723128 Webwww.amneal.com Phone(908) 947-3120Fax908-947-3146Employees7,600Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.67 High Stock Price Forecast$4.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+175.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.86) Trailing P/E RatioN/A Forward P/E Ratio2.66 P/E Growth0.12Net Income$-129,990,000.00 Net Margins-5.88% Pretax Margin-11.22% Return on Equity76.11% Return on Assets4.68% Debt Debt-to-Equity Ratio14.30 Current Ratio1.88 Quick Ratio1.17 Sales & Book Value Annual Sales$2.21 billion Price / Sales0.18 Cash Flow$1.23 per share Price / Cash Flow1.08 Book Value$0.61 per share Price / Book2.18Miscellaneous Outstanding Shares303,620,000Free Float222,309,000Market Cap$403.81 million OptionableOptionable Beta1.37 Key ExecutivesChintu PatelCo-Chief Executive Officer & DirectorChirag K. PatelPresident & Co-Chief Executive Officer & DirectorAndrew S. BoyerExecutive Vice President-Commercial OperationsAnastasios G. KonidarisExecutive VP, Chief Financial & Accounting OfficerNikita ShahChief Human Resources Officer & Executive VPKey CompetitorsRepare TherapeuticsNASDAQ:RPTXNurix TherapeuticsNASDAQ:NRIXEdgewise TherapeuticsNASDAQ:EWTXEmergent BioSolutionsNYSE:EBSLexicon PharmaceuticalsNASDAQ:LXRXView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 9,482 shares on 3/23/2023Ownership: 0.015%Alliancebernstein L.P.Bought 19,900 shares on 2/16/2023Ownership: 0.056%State of WyomingBought 24,333 shares on 2/16/2023Ownership: 0.025%State of Wisconsin Investment BoardSold 5,664 shares on 2/15/2023Ownership: 0.031%MetLife Investment Management LLCSold 9,482 shares on 2/15/2023Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions AMRX Stock - Frequently Asked Questions Should I buy or sell Amneal Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMRX shares. View AMRX analyst ratings or view top-rated stocks. What is Amneal Pharmaceuticals' stock price forecast for 2023? 3 Wall Street research analysts have issued 1 year price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price forecasts range from $3.00 to $4.00. On average, they anticipate the company's stock price to reach $3.67 in the next twelve months. This suggests a possible upside of 175.7% from the stock's current price. View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts. How have AMRX shares performed in 2023? Amneal Pharmaceuticals' stock was trading at $1.99 at the beginning of 2023. Since then, AMRX stock has decreased by 33.2% and is now trading at $1.33. View the best growth stocks for 2023 here. Are investors shorting Amneal Pharmaceuticals? Amneal Pharmaceuticals saw a decline in short interest in February. As of February 28th, there was short interest totaling 7,120,000 shares, a decline of 11.7% from the February 13th total of 8,060,000 shares. Based on an average daily volume of 1,290,000 shares, the short-interest ratio is currently 5.5 days. Approximately 7.2% of the shares of the company are sold short. View Amneal Pharmaceuticals' Short Interest. When is Amneal Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our AMRX earnings forecast. How were Amneal Pharmaceuticals' earnings last quarter? Amneal Pharmaceuticals, Inc. (NYSE:AMRX) posted its quarterly earnings data on Thursday, March, 2nd. The company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.19 by $0.02. The firm had revenue of $609.80 million for the quarter, compared to the consensus estimate of $579.93 million. Amneal Pharmaceuticals had a negative net margin of 5.88% and a positive trailing twelve-month return on equity of 76.11%. The firm's quarterly revenue was up 13.6% on a year-over-year basis. During the same period last year, the company earned $0.16 EPS. What guidance has Amneal Pharmaceuticals issued on next quarter's earnings? Amneal Pharmaceuticals issued an update on its FY23 earnings guidance on Thursday, March, 2nd. The company provided EPS guidance of $0.40-0.50 for the period, compared to the consensus earnings per share estimate of $0.77. The company issued revenue guidance of $2.25-2.35 billion, compared to the consensus revenue estimate of $2.31 billion. What is Chirag and Chintu Patel's approval rating as Amneal Pharmaceuticals' CEO? 23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Amneal Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC). What is Amneal Pharmaceuticals' stock symbol? Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX." Who are Amneal Pharmaceuticals' major shareholders? Amneal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Millennium Management LLC (1.65%), Morgan Stanley (1.39%), Norges Bank (0.89%), AQR Capital Management LLC (0.70%), Geode Capital Management LLC (0.60%) and Allspring Global Investments Holdings LLC (0.52%). Insiders that own company stock include Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc. View institutional ownership trends. How do I buy shares of Amneal Pharmaceuticals? Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amneal Pharmaceuticals' stock price today? One share of AMRX stock can currently be purchased for approximately $1.33. How much money does Amneal Pharmaceuticals make? Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $403.81 million and generates $2.21 billion in revenue each year. The company earns $-129,990,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. How many employees does Amneal Pharmaceuticals have? The company employs 7,600 workers across the globe. How can I contact Amneal Pharmaceuticals? Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146. This page (NYSE:AMRX) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.